Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes

Expert Review of Clinical Immunology

Volumn 6, Issue 6, 2010, Pages 831-841

  Church, Leigh D ^a   McDermott, Michael F ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

autoinflammatory; canakinumab; CAPS; IL 1 blocker; inflammasome

Indexed keywords

ALLOPURINOL; ANTIBIOTIC AGENT; CANAKINUMAB; COLCHICINE DERIVATIVE; METFORMIN; NEUTRALIZING ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT;

CINCA SYNDROME; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYSIPELAS; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; HEADACHE; HUMAN; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LONG TERM CARE; LOWER RESPIRATORY TRACT INFECTION; LUNG INFECTION; MAXIMUM PLASMA CONCENTRATION; MUCKLE WELLS SYNDROME; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYSEMIC ONSET JUVENILE IDIOPATHIC ARTHRITIS; SYSTEMIC ONSET JUVENILE IDIOPATHIC ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOMITING;

EID: 78049428295     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.66     Document Type: Review

References (56)

1. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-l β-processing infammasome with increased activity in Muckle-Wells autoinfammatory disorder. Immunity 20(3), 319-325 (2004).
2. Kile RL, Rusk HA. A case of cold urticaria with an unusual family history. JAMA 114, 1067-1068 (1940).
3. Church LD, Churchman SM, Hawkins PN, McDermott MF. Hereditary auto-infammatory disorders and biologics. Springer Semin. Immunopathol. 27(4), 494-508 (2006).
4. Muckle T, Wells M. Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome. Q. J. Med. 31235-31248 (1962).
5. Lorber J. Syndrome for diagnosis: dwarfng, persistently open fontanelle; recurrent meningitis; recurrent subdural effusions with temporary alternate-sided hemiplegia; high-tone deafness; visual defect with pseudopapilloedema; slowing intellectual development; recurrent acute polyarthritis; erythema marginatum, splenomegaly and iron-resistant hypochromic anaemia. Proc. R. Soc. Med. 66(11), 1070-1071 (1973).
6. Kummer JA, Broekhuizen R, Everett H et al. Infammasome components NALP 1 and 3 show distinct but separate expression profles in human tissues suggesting a site-specifc role in the infammatory response. J. Histochem. Cytochem. 55(5), 443-452 (2007).
7. Martinon F, Burns K, Tschopp J. The infammasome: a molecular platform triggering activation of infammatory caspases and processing of proIL-β. Mol. Cell 10(2), 417-426 (2002).
8. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 infammasome. Nature 440(7081), 237-241 (2006).
9. Cassel SL, Eisenbarth SC, Iyer SS et al. The Nalp3 infammasome is essential for the development of silicosis. Proc. Natl Acad. Sci. USA 105(26), 9035-9040 (2008).
10. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 infammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453(7198), 1122-1126 (2008).
11. Muruve DA, Petrilli V, Zaiss AK et al. The infammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452(7183), 103-107 (2008).
12. Petrilli V, Papin S, Dostert C, Mayor A, Martinon F, Tschopp J. Activation of the NALP3 infammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 14(9), 1583-1589 (2007).
13. Lachmann HJ, Lowe P, Felix SD et al. In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes. J. Exp. Med. 206(5), 1029-1036 (2009).
14. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N. Engl. J. Med. 348(25), 2583-2584 (2003).
15. Goldbach-Mansky R, Dailey NJ, Canna SW et al. Neonatal-onset multisystem infammatory disease responsive to interleukin-1β inhibition. N. Engl. J. Med. 355(6), 581-592 (2006).
16. Hoffman HM, Throne ML, Amar NJ et al. Effcacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 58(8), 2443-2452 (2008).
17. Dode C, Cuisset L, Delpech M, Grateau G. TNFRSF 1A-associated periodic syndrome (TRAPS), Muckle-Wells syndrome (MWS) and renal amyloidosis. J. Nephrol. 16(3), 435-437 (2003).
18. Hashkes PJ, Lovell DJ. Recognition of infantile-onset multisystem infammatory disease as a unique entity. J. Pediatr. 130(4), 513-515 (1997).
19. Church LD, Cook GP, McDermott MF. Primer: infammasomes and interleukin 1β in infammatory disorders. Nat Clin. Pract. Rheumatol. 4(1), 34-42 (2008).
20. Hawkins PN, Bybee A, Aganna E, McDermott MF. Response to anakinra in a de novo case of neonatal-onset multisystem infammatory disease. Arthritis Rheum. 50(8), 2708-2709 (2004).
21. Hoffman HM, Rosengren S, Boyle DL et al. Prevention of cold-associated acute infammation in familial cold autoinfammatory syndrome by interleukin-1 receptor antagonist. Lancet 364(9447), 1779-1785 (2004).
22. Leslie KS, Lachmann HJ, Bruning E et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinfammatory disease associated with CIAS-1/NALP3 mutations. Arch. Dermatol. 142(12), 1591-1597 (2006).
23. Maksimovic L, Stirnemann J, Caux F et al. New CIAS1 mutation and anakinra effcacy in overlapping of Muckle-Wells and familial cold autoinfammatory syndromes. Rheumatology (Oxford) 47(3), 309-310 (2008).
24. Mirault T, Launay D, Cuisset L et al. Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. Arthritis Rheum. 54(5), 1697-1700 (2006).
25. O'Connell SM, O'Regan GM, Bolger T et al. Response to IL-1-receptor antagonist in a child with familial cold autoinfammatory syndrome. Pediatr. Dermatol. 24(1), 85-89 (2007).
26. Ross JB, Finlayson LA, Klotz PJ et al. Use of anakinra (Kineret) in the treatment of familial cold autoinfammatory syndrome with a 16-month follow-up. J. Cutan. Med. Surg. 12(1), 8-16 (2008).
27. Rynne M, Maclean C, Bybee A, McDermott MF, Emery P. Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism. Ann. Rheum. Dis. 65(4), 533-534 (2006).
28. Neven B, Marvillet I, Terrada C et al. Long-term effcacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem infammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 62(1), 258-267 (2010).
29. Miyamae T, Inaba Y, Nishimura G et al. Effect of anakinra on arthropathy in CINCA/NOMID syndrome. Pediatr. Rheumatol. Online J. 8, 9 (2010).
30. Ratner M. IL-1 trap go-ahead. Nat Biotechnol. 26(5), 485 (2008).
31. Goldbach-Mansky R, Shroff SD, Wilson M et al. A pilot study to evaluate the safety and effcacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 trap) in patients with familial cold autoinfammatory syndrome. Arthritis Rheum. 58(8), 2432-2442 (2008).
32. Hashkes P, Lovell D, Giannini E, Huang B, Kastner D. Rilonacept (IL-1 trap) for treatment of colchicine resistant familial mediterranean fever: a randomized, multicenter double-blinded, alternating treatment (n of 1) trial. Clin. Exp. Rheumatol. 26(2), 193 (2008).
33. Lovell D, Giannini E, Kimura Y et al. Preliminary evidence for bioactivity of IL-1 trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis. Ann. Rheum. Dis. 65(Suppl. 2), 693 (2006).
34. Lovell DJ, Giannini EH, Kimura Y et al. Preliminary evidence for bioactivity of IL-1 trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis (SJIA). Arthritis Rheum. 54(9), S325-S326 (2006).
35. Radin A, Terkeltaub R, Schumacher H et al. Placebo-controlled pilot study of rilonacept (IL-1 trap), a long acting IL-1 inhibitor, in refractory chronic active gouty arthritis. Clin. Exp. Rheumatol. 26(2), 181-181 (2008).
36. Terkeltaub R, Schumacher HR, Sundy J et al. Placebo-controlled pilot study of rilonacept (IL-1 trap), a long acting IL-1 inhibitor, in refractory chronic active gouty arthritis. Arthritis Rheum. 56(12), 4231-4232 (2007).
37. Novartis preclinical research day. Novartis AG Company Presentation. 3 May 2005.
38. Investor relations: pharmaceutical pipeline event. Novartis AG company presentation. 20 September 2005.
39. Cook GP, Savic S, Wittmann M, McDermott MF. The NLRP3 infammasome, a target for therapy in diverse disease states. Eur. J. Immunol. 40(3), 631-634 (2010).
40. Fishwild DM, O'Donnell SL, Bengoechea T et al. High-avidity human IgG? monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol. 14(7), 845-851 (1996).
41. th Annual Congress of the European Respiratory Society. Munich, Germany, 2-6 September 2006 (Abstract 748).
42. Alten R, Gram H, Joosten LA et al. The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint infammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res.Ther. 10(3), R67 (2008).
43. Alten R, Pohl C, Batard Y et al. ACR 20/50/70 responses in methotrexate(MTX)-resistent rheumatoid arthritis (RA) patients in a double-blind, placebo (PBO)-controlled Phase I/II evaluation of the pharmacokinetics/pharmacodynamics (PK/PD), safety, and preliminary effcacy of a fully human anti interleukin 1 antibody. Ann. Rheum. Dis. 67(Suppl. 2), OP0178 (2007).
44. Gattorno M, Tassi S, Carta S et al. Pattern of interleukin-1β secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum. 56(9), 3138-3148 (2007).
45. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360(23), 2416-2425 (2009).
46. Kuemmerle-Deschner JB, Tzaribachev N, Hausmann S et al. Long-lasting response to ACZ885 (a new human IgG1 anti-IL-1β monoclonal antibody) in patients with Muckle-Wells syndrome (MWS). Clin. Exp. Rheumatol. 26(2), 180 (2008).
47. Lachmann HJ, Jung T, Bobadilla M et al. Treatment of Muckle-Wells syndrome with a fully human anti-IL-1β monoclonal antibody (ACZ885)-initial results from a proof of concept study Ann. Rheum. Dis. 65(Suppl. 2), 76 (2006).
48. Lachmann H, Jung T, Felix S et al. Treatment of cryopyrin associated periodic fever syndrome with a fully human anti-IL-1β monoclonal antibody (ACZ885): results from a subcutaneous administration study. Clin. Exp. Rheumatol. 26(2), 181 (2008).
49. Kuemmerle-Deschner JB, Tzaribachev N, Hansmann S et al. Long lasting response to ACZ885 in patients with Muckle-Wells syndrome (MWS). Ann. Rheum. Dis. 67(Suppl. 2), 104 (2008).
50. Kuemmerle-Deschner JB, Blank N, Roesdler J et al. ACZ885 (canakinumab), a new IL-1β blocking monoclonal antibody provides long-lasting remission in children with cryopyrin asociated periodic syndromes (CAPS). Arthritis Rheum. 58(9 Suppl.), S633 (2008).
51. Ruperto N, Quartier P, Wulffraat N et al. ACZ885 (canakinumab), a new IL-1β blocking monoclonal antibody has a benefcial effect in children with systemic juvenile idiopathic arthritis (SJIA). Arthritis Rheum. 58(9 Suppl.), S942-S943 (2008).
52. Ruperto N, Quartier P, Wulffraat N et al. A Phase II trial with canakinumab, a new IL-1β blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and effcacy profle in children with systemic juvenile idiopathic arthritis (SJIA). Paediatr. Rheumatol. Online J. 6(Suppl. 1), S2 (2008).
53. th Annual Congress of the European Respiratory Society. Munich, Germany, 2-6 September 2006 (Abstract 752).
54. Kuemmerle-Deschner JB, Blank N, Roesler J et al. ACZ885 (canakinumab), a new IL-1β blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome. Paediatr. Rheumatol. Online J. 6(Suppl. 1), S26 (2008).
55. Allantaz F, Chaussabel D, Stichweh D et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J. Exp. Med. 204(9), 2131-2144 (2007).
56. Buch M, Bingham S, Seto Y et al. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor α blockade. Arthritis Rheum. 50(3), 725-728 (2004).